ACS Dobfar S.p.A., a leading chemical-pharmaceutical group specialising in the development and production of active pharmaceutical ingredients and pharmaceutical formulations, with 22 manufacturing sites worldwide (13 of which are in Italy), has completed the acquisition of Istituto Biochimico Italiano G. Lorenzini (IBI) and its subsidiaries, a historic Italian excellence that has been active in the pharmaceutical sector for 108 years.
The transaction represents an important strategic step in ACS Dobfar’s growth path, consolidating the Group’s vertical integration strategy and strengthening its ability to ensure continuity and reliability in pharmaceutical supply. The acquisition will also allow ACS Dobfar to increase its presence in the countries where IBI already operates directly, and to strengthen the global production and distribution of sterile hospital products and injectable penicillin antibiotic vials.
LCA Studio Legale advised ACS Dobfar S.p.A. as purchaser with a team led by Senior Partner Daniele Bonvicini and composed of Senior Associate Lara Bianchini, Associates Ginevra Losi and Carolina Cominardi, and Trainee Fabrizio Miceli.
International law firm Gianni & Origoni advised Istituto Biochimico Italiano G. Lorenzini and the outgoing ownership with a team composed of Partner Chiara Gianni, Managing Associate Niccolò Lavorano, Associates Niccolò Filippo Frattari and Flaminia Sampietro for corporate and M&A matters, Partner Antonio Lirosi and Counsel Cinzia Guglielmello for administrative aspects, Partner Fabio Chiarenza, Of Counsel Sandro Maria Galardo and Managing Associate Alessandro Minniti for tax matters, Partner Cristina Capitanio and Managing Associate Eleonora Rainaldi for labour law matters, and Managing Associate Angela Tasillo for IP matters.
Read the news: Legalcommunity
